Free webseminars

Welcome to geneXplain’s free webseminars!

 

 

Upcoming webseminars:

 

We will announce the next webseminar soon.

Stay tuned to our news!

 

Recent webseminars

 

Regulatory SNPs in TRANSFAC® sites. Severe COVID-19 patients versus non-symptomatic.

This webseminar was held on August 5th, 2020, at 06:00 PM CEST

The webseminar was given by geneXplain’s CSO Dr. Alexander Kel.

Webseminar brief summary:

More then 90% of disease-linked SNPs are non-coding. So, they are located outside of the protein coding regions of genome and often mark the genomic regions that regulate genes whose aberrant expression leads to dysfunction of signal transduction or metabolic pathways leading to the elevated disease susceptibility or severity. Such regulatory SNPs are difficult to interpret since the regulatory code is still purely understood.  Regulatory SNPs are often associated with DNA sequence variations that effect transcription factor bindings sites (TFBSs), which leads to the change in regulation of the target genes. We used TRANSFAC® database and the geneXplain® platform with the automatic omics analysis tool Genome Enhancer to analyze TFBS of SNPs revealed in GWAS study in the COVID-19 Host Genetics Initiative, which is a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 28, 715–718 (2020). https://doi.org/10.1038/s41431-020-0636-6.

We revealed TFBSs (for such TFs as FOXO1, TCF3, E2F1, TP53) strongly associated with SNPs linked with the severity of COVID-19 disease. Upstream analysis of these TFs in the context of the reveled SNPs gave us a clue about signal transduction pathways associated with the potential predisposition to the severe COVID-19 disease.

We will publish the video record of this webseminar soon.
 

COVID-19 Challenge: Known unknowns and unknown unknowns in biological activity spectra of the current and emerging pharmaceutical agents

This video is a record of geneXplain’s live webseminar ‘COVID-19 Challenge: Known unknowns and unknown unknowns in biological activity spectra of the current and emerging pharmaceutical agents’ which was held on June 24th, 2020.

This webseminar was given by our invited speaker, Prof. Vladimir Poroikov from the Institute of Biomedical Chemistry (IBMC), Moscow, Russia.

At the webseminar Prof. Vladimir Poroikov showed how to apply human intelligence and machine learning methods to in silico analysis of biological activity profiles of the launched and investigational drugs currently proposed for the pharmacotherapy of multifaceted clinical manifestations of SARS-CoV-2 infection.

Particular emphasis was placed on PharmaExpert software that analyzes the biological activity spectra predicted by PASS taking into account the relationships between different biological activities, and identifies the pleiotropic effects of drug combinations and preparations of medicinal plants.

 

COVID-19 Challenge: In silico approach to finding potential anti-SARS-CoV-2 agents among one billion molecules

This video is a record of geneXplain’s live webseminar ‘COVID-19 Challenge: In silico approach to finding potential anti-SARS-CoV-2 agents among one billion molecules’ which was held on May 13th, 2020.

This webseminar was given by our invited speaker, Prof. Vladimir Poroikov from the Institute of Biomedical Chemistry (IBMC), Moscow, Russia.

At the webseminar Prof. Vladimir Poroikov showed how to apply artificial intelligence and machine learning methods to in silico screening of hits with the desired biological activity in chemical libraries of synthesized or virtual molecules.

Particular emphasis was placed on PASS (Prediction of Activity Spectra for Substances), one of the earliest and most widely used software for the elucidation of hidden pharmacological potential of drug-like molecules.

 

COVID-19 – online discovery of prospective drug targets and personalized treatments with Genome Enhancer

This video is a record of geneXplain’s live webseminar ‘COVID-19 – online discovery of prospective drug targets and personalized treatments with Genome Enhancer’ which was held on April 29th, 2020.

In this video geneXplain’s CSO Dr. Alexander Kel is performing the analysis of personalized transcriptomics data coming from bronchoalveolar lavage of certain COVID-19 patients using the Genome Enhancer software.

 

COVID-19 – online discovery of prospective drug targets and treatments with Genome Enhancer

This video is a record of geneXplain’s live webseminar ‘COVID-19 – online discovery of prospective drug targets and treatments with Genome Enhancer’ which was held on April 7th, 2020.

In this video geneXplain’s CSO Dr. Alexander Kel is performing the integrated analysis of transcriptomics and proteomics datasets of COVID-19 patient data in search for prospective drug targets and treatments using the Genome Enhancer software.

Thank you for your interest in our webseminars!

If you have any suggestions for new topics of our webseminars, please let us know via info@genexplain.com, and maybe your topic will be selected for one of the next webseminars!

×